TAK-659 + venetoclax

TAK-659 + venetoclax is an investigational **combination therapy** being tested primarily for relapsed or refractory non-Hodgkin lymphoma. - **TAK-659** (also known as mivavotinib) is a small molecule inhibitor that targets spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3), leading to the disruption of B-cell receptor (BCR) signaling and suppression of malignant B-cell proliferation[8][1]. - **Venetoclax** is a small molecule oral inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL-2), triggering apoptosis in malignant cells dependent on BCL-2 for survival[2]. The combination aims to leverage synergistic mechanisms—interrupting critical cell survival pathways and enabling apoptosis in hematologic malignancies such as non-Hodgkin lymphoma. It is under investigation in early-phase trials for adults with relapsed or refractory non-Hodgkin lymphoma[1][3][5].

Other names

mivavotinib + venetoclax